报告题目:Targeting Tumor Microenvironment for Cancer Therapy
报 告 人：Leaf Huang, Ph.D., Distinguished Professor
Pharmacoengineering and Molecular Pharmaceutics in the Eshelman School of Pharmacy,
University of North Carolina at Chapel Hill.
主 持 人：陈华兵教授
黄力夫博士，美国北卡罗莱纳大学教堂山分校Eshelman药学院教授，长期从事分子药剂学研究，主要研究方向为基因治疗及靶向药物递送。在Advanced Materials、Advanced Drug Delivery Reviews、Nature Communications、ACS Nano、Biomaterials、Journal of Controlled Release等高水平杂志上发表600余篇SCI论文，他引超过3万次，H-index为120；很多工作被选为焦点文章、封面文章等，2013年被评为美国杰出药物科学家。
Dr. Huang’s research has been in the area of gene therapy and targeted drug delivery. He has pioneered the liposome non-viral vector and has designed and manufactured the cationic lipid vector for the first non-viral clinical trial in 1992. His current work centers on nanoparticle vectors for gene transfer in tumor and liver. He also continues research in establishing a ligand targeted delivery system for cDNA, mRNA, siRNA, proteins and peptides for tumor growth inhibition and for vaccines in treating cancer and infected diseases.He has authored or co-authored more than 600 papers with an H-index of 120. He is also the inventor or co-inventor of 22 US and foreign patents. In 2004, he received the Alec D. Bangham MD FRS Achievement Award, which is the highest honor in liposome research. He was the recipient of the 2013 Distinguished Pharmaceutical Scientist Award which is the highest scientific recognition of the American Association of Pharmaceutical Scientists. Dr. Huang has also co-founded 6 biotech start-ups in the past.